Sentences with phrase «n't change the risk»

They found that children who were sicker upon arrival at the hospital were more likely to die from their illness, not from the spinal tap, which did not change their risk of death.

While baseline decaffeinated coffee consumption was associated with a lower type 2 diabetes risk, the changes in decaffeinated coffee consumption did not change this risk.

They found that low - dose radiation didn't change the risk of cancer in most mice.

It does not change the risk assessment for changing the atmospheric composition.

Does not change the risk of an extreme event happening but produces a lot of comfort in the organization which is good for morale.

You also can't change the risk level from aggressive to conservative or anywhere on the spectrum.

Not exact matches

The U.S., he said, risks falling behind other countries economically if it doesn't make a change.

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Shum and Colaco point out that any reclassification of risk would be heavily scrutinized by Canadian regulators, in order to make sure that changes aren't self - serving on the part of policy providers and in fact benefit consumers.

Such statements are based on management's current views and assumptions that could ultimately prove inaccurate and are subject to risk factors such as (but not limited to) changes in raw materials prices, currency fluctuations, the pace at which cost - reduction projects are implemented and changes in general economic and financial conditions.

His question to them: «If I'm completely stupid in a world that is changing beyond recognition, in ways that we can not imagine at this point in time, and we do not take account of it in our decision - making, what is the likelihood that I will end up with value at risk?»

«Zika virus is known to be circulating in South - East Asia Region and these findings do not change the global risk assessment.»

Certain matters discussed in this news release are forward - looking statements that involve a number of risks and uncertainties including, but not limited to, doubts about the Company's ability to continue as a going concern, the need to obtain additional funding, risks in product development plans and schedules, rapid technological change, changes and delays in product approval and introduction, customer acceptance of new products, the impact of competitive products and pricing, market acceptance, the lengthy sales cycle, proprietary rights of the Company and its competitors, risk of operations in Israel, government regulations, dependence on third parties to manufacture products, general economic conditions and other risk factors detailed in the Company's filings with the United States Securities and Exchange Commission.

So, although «the risk of climate change is clear and the risk warrants action» (in the form of greater energy efficiency and emissions - reducing technology), the big oil company will not be writing down any of its reserves.

«That was just not sustainable and certainly not healthy, and greatly increased the risk of a severe correction if economic circumstances changed.»

But if climate change isn't stabilized soon, the authors wrote,» [t] he large - scale loss of functionally diverse corals is a harbinger of further radical shifts in the condition and dynamics of all ecosystems, reinforcing the need for risk assessment of ecosystem collapse.»

«In a world that's changing really quickly, the only strategy that is guaranteed to fail is not taking risks.»

But Mills and other experts don't expect banks to change their risk - averse policies.

Separately on Monday, Germany - based Bayer said Essure's benefit or risk profile had not changed and that the company remains positive about the product.

There's a Real Risk That Trump's Trade War With China Won't Change Anything TIME The Case of Hong Kong's Missing Booksellers New York Times A Hong Kong Newspaper on a Mission to Promote China's Soft Power New York Times Was Letting China Into the WTO a Mistake?

However, when that didn't work out, his team took a risk, which entirely changed the company's trajectory.

At the risk of overgeneralizing, these optimism - fueled parts of the U.S. aren't the centers of discontent that chose change for change's sake.

If it's not an order of magnitude better or cheaper, customers usually conclude that the risk and cost of change are simply not worth the potential payback over what they have today.

Although it may seem like a risk to drastically change up the way you've been doing things for so many years, it's a risk you can't afford not to take.

While I don't believe the project was cancelled because of risks from proposed changes to GHG policies in B.C., it's certainly possible that any change in GHG policy would have a material impact on the expected costs of liquefaction.

«We do not believe that the outlook and balance of risks warrants a position of no policy change, nor a position of rapid easings,» said Reserve Bank of New Zealand Governor Graeme Wheeler in a speech to businesspeople in Dunedin, the text of which was released on the bank's website.

Getting your people on board with the shift is crucial, adds Gareri; leaders risk creating fear instead of motivation if they don't clearly communicate what the change involves and why it is necessary.

cameras, illustrates the risks that consumers are taking by not changing the default passwords on camera enabled devices.

«The fact that a website is able to stream footage from thousands of cameras, illustrates the risks that consumers are taking by not changing the default passwords on camera enabled devices.

Companies as diverse as Square, Snapchat and Apple are trying to disrupt financial services in their own way, and the banks, accustomed to enjoying an oligopoly in Canada, can't risk getting caught off guard by technological change.

Some say an exit interview is the ideal opportunity to be completely honest about your experiences with your employer and offer them critical and constructive feedback, while others argue it's awkward and not worth the risk of burning bridges, as your criticism probably won't inspire any significant changes, anyway.

When you don't, you risk missing game - changing opportunities.

Zuckerberg said of the self - made billionaire: «Peter was the person who told me this really pithy quote: «In a world that's changing so quickly, the biggest risk you can take is not taking any risk.»

Education can make people better accountants, economists and better at tax law, but it can't effectively change risk preferences, and it can't change genetics.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

These risks include, in no particular order, the following: the trends toward more high - definition, on - demand and anytime, anywhere video will not continue to develop at its current pace or will expire; the possibility that our products will not generate sales that are commensurate with our expectations or that our cost of revenue or operating expenses may exceed our expectations; the mix of products and services sold in various geographies and the effect it has on gross margins; delays or decreases in capital spending in the cable, satellite, telco, broadcast and media industries; customer concentration and consolidation; the impact of general economic conditions on our sales and operations; our ability to develop new and enhanced products in a timely manner and market acceptance of our new or existing products; losses of one or more key customers; risks associated with our international operations; exchange rate fluctuations of the currencies in which we conduct business; risks associated with our CableOS ™ and VOS ™ product solutions; dependence on market acceptance of various types of broadband services, on the adoption of new broadband technologies and on broadband industry trends; inventory management; the lack of timely availability of parts or raw materials necessary to produce our products; the impact of increases in the prices of raw materials and oil; the effect of competition, on both revenue and gross margins; difficulties associated with rapid technological changes in our markets; risks associated with unpredictable sales cycles; our dependence on contract manufacturers and sole or limited source suppliers; and the effect on our business of natural disasters.

For example, the expected timing and likelihood of completion of the proposed merger, including the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the proposed merger that could reduce anticipated benefits or cause the parties to abandon the transaction, the ability to successfully integrate the businesses, the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, the possibility that Kraft shareholders may not approve the merger agreement, the risk that the parties may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all, risks related to disruption of management time from ongoing business operations due to the proposed transaction, the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Kraft's common stock, and the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Kraft and Heinz to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally, problems may arise in successfully integrating the businesses of the companies, which may result in the combined company not operating as effectively and efficiently as expected, the combined company may be unable to achieve cost - cutting synergies or it may take longer than expected to achieve those synergies, and other factors.

A balanced approach to investing in bonds is probably the safest way to spread your interest rates risks and take advantage of changing rates since we won't be able to predict how things will work out.

Inflation risk: is the chance that cash flow from an investment won't be worth as much in the future because of changes in purchasing power due to inflation.

«There's always the additional risk that these secular changes are not just random wanderings, which will eventually work themselves out, but justified permanent changes in levels.

«Those who sit around and don't change and aren't willing to take risk are out of business.»

At its heart it's impossible to call any form of link building «low risk» since Google is always changing its algorithm to flag links that aren't natural and because inherent in «link building» is the intention to build links for the purpose of convincing Google that your website is more authoritative than it would naturally be without link building.

True, it was only one quarter's information and that was not enough to change our numerical forecast of inflation, but it did lead us to conclude in our May Statement on Monetary Policy that there was no longer an upward risk to our inflation forecast.

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

Even if income does not change by much, wealth can rise or fall because of changes in the attitude of investors toward risk, and declines in the value of collateral behind debt.

We believe a step - up in risk aversion has led to a structural rise in precautionary savings, further dragging down bond yields across the curve — a trend that won't quickly change, as we write in our Global macro outlook The safety premium driving low rates.

All of this could easily change when U.S. markets open, when investors ponder the new and more volatile environment they live in, when traders decide they do not want to bear risk over the weekend, or when a weekend of pondering leads to a wave of liquidations on Monday morning.

«We can not escape the need for change, but if we do our utmost to respond wisely to the challenges these risks present, we believe that not only can we address the risk, we can build a more sustainable future,» says Morten Jastrup, Project Director of the Global Opportunity Network.

As you grow your assets to the hundreds of thousands or millions of dollars, you aren't going to be whipping around your capital as easily as before because your risk tolerance will change.

Ratings by S&P and Fitch apply to the credit quality of a portfolio and are not a recommendation to buy, sell or hold securities of a fund, are subject to change, and do not remove market risks associated with investments in the fund.